Rigel Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs CADL, IMMX, AURA: Days Payable Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rigel Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Days Payable of 114.73 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rigel Pharmaceuticals and its competitors. This is 92% below median its historical median of 1,433.36. Over the past decade, Rigel Pharmaceuticals' Days Payable has ranged from 97.94 to 5,740.17. According to the industry distribution chart, Rigel Pharmaceuticals ranks #378 out of 706 companies in the Biotechnology industry, placing it in the top 53.5%.
Is Rigel Pharmaceuticals' Days Payable too high?
Rigel Pharmaceuticals' current Days Payable of 114.73 is 92% below median its 10-year median of 1,433.36. Over the past 10 years, this metric has ranged from a low of 97.94 to a high of 5,740.17. The Biotechnology industry median Days Payable is 113.56. Rigel Pharmaceuticals' value of 114.73 is 1% above this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #378 out of 706 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Days Payable compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #378 out of 706 companies for Days Payable. This places Rigel Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Rigel Pharmaceuticals' value of 114.73 is 1% above this benchmark. Historically, Rigel Pharmaceuticals' own Days Payable has ranged from 97.94 to 5,740.17 over the past decade. While the company's 10-year median is 1,433.36 vs. the industry median of 113.56, Rigel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Days Payable of 114.73 is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Days Payable is 114.73, which is 92% below median its own 10-year median of 1,433.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Days Payable of 114.73. The stock's GF Value™ is €23.38, compared to a current price of €31.86 — trading 36.3% above its estimated fair value. The current Days Payable is 114.73, which is 92% below median its 10-year median of 1,433.36 and 1% above the Biotechnology industry median of 113.56. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Days Payable is 114.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €31.86 is trading 36.3% above its estimated GF Value™ of €23.38.
Key valuation signals for FRA:RI2:
Days Payable: 114.73 (92% below median its 10-year median of 1,433.36)
GF Value™: €23.38 vs. price of €31.86 (36.3% above fair value)
Industry Position: 1% above the Biotechnology median (#378 of 706)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score
Get the complete analysis for FRA:RI2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
